Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Tuesday 12 February, 2008

Lipoxen PLC

Lipoxen Patent Grant

Lipoxen PLC
12 February 2008

   Lipoxen reports significant progress in the development of its DNA vaccine
                           delivery patent portfolio

       US grant one of Lipoxen's foundation patents which forms the basis
                              of ImuXen technology

London, UK, 12 February 2008 - Lipoxen PLC, (AIM:LPX) a bio-pharmaceutical
company specialising in the development of high value differentiated
biologicals, vaccines and oncology drugs, announces today that one of its
cornerstone patents (No 10/617734) has been allowed in the US, following on from
it being granted in Europe and other territories.

The patent covers the encapsulation of DNA inside a liposome. This protects the
DNA from enzyme degradation and allows more efficient DNA delivery to the immune
system which results in the vaccination being more effective. DNA vaccines have
a number of advantages over traditional products, including safety, ease of
manufacture and a reduced cost.

ImuXen, Lipoxen's advanced enabling technology, has built further on this
advancement as it allows the co-delivery of both DNA vaccine and the protein it
encodes. The advantage of the follow-on ImuXen technology, which is being used
in the development of a candidate vaccine for hepatitis B and E (HepaXen) by
Lipoxen, is that by encapsulating both the DNA and the protein it encodes an
even more enhanced immune response can be generated. Studies with a hepatitis E
vaccine candidate have already shown the generation of strong protective immune
responses in a relevant model.

Lipoxen has been granted patents on the liposomal encapsulation of DNA in Europe
and China, and HepaXen is being developed with Lipoxen's partner, the Serum
Institute of India.

The US patent that has been granted will act to protect Lipoxen's position in
the field of DNA vaccine delivery technology and will help ensure that its
advanced ImuXen technology will continue to be at the forefront of novel vaccine
development.

M. Scott Maguire, CEO of Lipoxen, said:

'Lipoxen is pleased that the novelty and utility of its DNA vaccine technology
has been recognised by the grant of a key US patent. While we imagine that many
DNA vaccines may benefit from ImuXen's co-delivery approach, some may also
generate effective immune responses based on liposomal DNA alone. The
intellectual property portfolio that Lipoxen is continually developing in the
vaccine delivery area should enable Lipoxen to carve out an important position
in the development of novel vaccines which address some of the world's most
infectious diseases. With the progress we are continuing to make in DNA vaccine
delivery technology coupled with the first clinical data for our two most
advanced high-value differentiated protein biologicals expected before mid 2008,
Lipoxen is well positioned for the future in both protein drug and vaccine
fields.'


                                      Ends

Enquiries

Lipoxen PLC
M. Scott Maguire, Chief Executive Officer             +44 (0)20 7691 3583

Landsbanki Securities (UK) Limited (nominated
adviser)
Shaun Dobson / Claes Spang                            +44 (0)20 7426 9000

Citigate Dewe Rogerson                                +44 (0)20 7638 9571
David Dible / Emma Palmer


Notes to Editors

Lipoxen PLC (AIM:LPX) is a biopharmaceutical company specializing in the
development of high value differentiated biologicals, vaccines and oncology
drugs. Products currently under development include improved formulations of
important biologicals such as erythropoietin (EPO), G-CSF, insulin and
Interferon-alpha. Lipoxen has two products in clinical development SuliXen, a
long acting insulin and long-acting EPO. These novel products, which are based
on Lipoxen's proprietary PolyXen(R) technology, each address markets in excess
of US$1 billion.

Lipoxen's technology is designed to improve the stability, biological half-life
and immunologic characteristics of therapeutic proteins naturally. Lipoxen has
two further naturally-derived proprietary delivery technologies, ImuXen(R) and a
related liposomal technology for the formulation of cytotoxic oncology drugs,
which are being developed to enhance the efficacy and safety of various vaccines
such as a multivalent Hepatitis B-E and pneumococcal vaccines, as well as a
number of anti-cancer agents like paclitaxel. The Company's proprietary delivery
technologies are attracting significant interest and Lipoxen is currently
co-developing products with the Serum Institute of India Limited (one of the
world's leading vaccine companies, India's largest biotech company and a major
shareholder in Lipoxen) and has license agreements in place with Baxter
International and InterVet, a leading animal health company.

Lipoxen was admitted to trading on the AIM Market of the London Stock Exchange
in January 2006.

This announcement includes 'forward-looking statements' which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Company's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Company's products and services), and any
statements preceded by, followed by or that include forward-looking terminology
such as the words 'targets', 'believes', 'estimates', 'expects', 'aims',
'intends', 'will', 'can', 'may', 'anticipates', 'would', 'should', 'could' or
similar expressions or the negative thereof. Such forward-looking statements
involve known and unknown risks, uncertainties and other important factors
beyond the Company's control that could cause the actual results, performance or
achievements of the Company to be materially different from future results,
performance or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements are based on numerous assumptions
regarding the Company's present and future business strategies and the
environment in which the Company will operate in the future. Among the important
factors that could cause the Company's actual results, performance or
achievements to differ materially from those in forward-looking statements
include those relating to The Company's funding requirements, regulatory
approvals, clinical trials, reliance on third parties, intellectual property,
key personnel and other factors. These forward-looking statements speak only as
at the date of this announcement. The Company expressly disclaims any obligation
or undertaking to disseminate any updates or revisions to any forward-looking
statements contained in this announcement  to reflect any change in the
Company's expectations with regard thereto or any change in events, conditions
or circumstances on which any such statements are based. As a result of these
factors, readers are cautioned not to rely on any forward-looking statement.


                      This information is provided by RNS
            The company news service from the London Stock Exchange